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THE SUCCESS OF AUTOLOGOUS TRANSPLANT FOR PEDIATRIC RE-
LAPSED/REFRACTORY HODGKIN LYMPHOMA IS MOST INFLUENCED BY
THE DISEASE STATUS PRE-TRANSPLANT
Margossian, S.P.,Williams, T., Billett, A.L., Duncan, C., Lehmann, L.E.
Dana Farber/Children’s Hospital Cancer Center, Boston, MA
Background: Autologous peripheral blood stem cell transplant
(aPBSCT) is a standard treatment approach for patients with re-
lapsed or refractory Hodgkin Lymphoma (HL). The current liter-
ature suggests the 3 year event free survival for HL patients
following aPBSCT ranges from 40-65% with 5% events due
to transplant related mortality and recurrent disease accounting
for the rest.
Methods:We conducted a retrospective analysis of all pediatric pa-
tients who were transplanted for HL at the DF/CHCC from 1/1/00
to 12/31/09. 24 patients with refractory (n5 9) or relapsed (n5 15)
HL underwent aPBSCT, including 2 patients with multiple relapses
and one with initial refractory disease who subsequently progressed
prior to aPBSCT (scored as refractory). Any patient whose disease
progressed during first therapy was considered refractory, even if
there was an initial disease response.
Patients:There were 13 males and 11 females analyzed, average age
14 yrs (8 yr-20.5 yr). Disease stage at presentation ranged from IIa to
IVb. Histology included NS (n 5 20), mixed cellularity (n 5 3) and
LP (n5 1). Disease progression/recurrence was confirmed by biopsy
in 22 of 24 patients. Salvage regimens varied, with ICE (n5 12) and
venorelbine regimens (n 5 9) most common.
Results: 22/24 patients came to transplant in CR (defined as
negative functional study and . 50% tumor response by CT);
1/24 in VGPR (defined as negative functional study and\ 50%
CT response) and 1/24 with active disease on PET with 50% re-
sponse by CT. All patients were conditioned with BEAM
(carmustine/etoposide/cytarabine/melphalan) followed by reinfu-
sion of cryopreserved autologous cells. There was 1 toxic death
at day +12 (4%) in a patient previously intubated for Stevens-
Johnson syndrome, and 1 relapse (4%) occurring 6 months after
aPBSCT.
Conclusion: aPBSCT is a proven modality to salvage patients with
HL who fail frontline therapy. In our series, conditioning with
BEAM followed by aPBSCT had a TRM (4 %) consistent with
that reported for autologous transplant. Disease progression was
seen in only one patient. Notably this was the only patient with func-
tional evidence of active disease at time of transplant. 92% (22/24) of
patients who presented for aPBSCT are alive and well with a median
follow-up of 60 months. Length of first CR, stage of disease or num-
ber of relapses prior to transplant did not seem to impact survival.
These results suggest achieving excellent EFS is most influenced
by disease control pre-aPBSCT.314
PROCALCITONIN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT (AHSCT) RECIPIENTS
Watson, T.M.1, Fry, T.J.2, Jacobsohn, D.A.1, Sande, J.1,3, Yates, B.1,
Stevenson, A.1 1Children’s National Medical Center, Washington, DC;
2Center for Cancer Research, NCI, NIH, Bethesda, MD; 3George Wash-
ington University School of Medicine, Washington, DC
The mortality of aHSCT remains unacceptably high and is of-
ten related to inflammation from infection and/or graft-versus-
host disease (GVHD). Identifying markers of inflammation may
allow tailoring of therapy in high-risk patients (pts). Studies
show PCT as a useful marker in assessing the severity of bacterial
infections. We conducted a prospective pilot study measuring
serial procalcitonin (PCT) and other inflammatory markers in pe-
diatric aHSCT pts. The goal of this ongoing study is to identify
biomarkers that would be predictive of infection and other post-
transplant complications.
Pts were enrolled prior to preparative regimen, and serum was
collected pre-transplant, day of stem cell infusion (D0), biweeklyuntil engraftment, and on day 30, 60, and 100. Samples were
run using Time Resolved Amplified Cryptate Emission technol-
ogy.
Thirteen pts have been enrolled, with a median age of 10 (1-21)
years and the following diagnoses: AML (4), ALL (2), bone marrow
failure (4), thalassemia (2), and sickle cell disease (1). Stem cell
sources include HLA matched related donor (4), matched unrelated
donor (8), and sibling cord (1). The conditioning regimen was abla-
tive in 7 and reduced intensity in 6.
To date, we have pre-transplant and D0 data on all pts. Median
PCT values showed significant differences at the 2 time points
(pre-transplant 0.105 ng/dl [0.000-0.350] vs D0 0.315 ng/dl
[0.035-7.230], p 0.02] with no effect from conditioning regimen.
Of pts with blood culture positive sepsis (2), neither had PCT .
2.0 ng/dl. Pts with GVHD (6) did not have an elevation in PCT.
One pt requiring intensive care for acute renal failure and develop-
ment of respiratory failure due to parainfluenza had significantly el-
evated PCT (peak 20 ng/dl).
This data suggest that an elevation in PCT on D0 is associated
with inflammation caused by preparative regimens. Although the
exact mechanism of PCT is unknown, it is hypothesized that
PCT synthesis is induced by TNF-a or IL-6, which are known
to play a role in preparative regimen-induced inflammation. We
are currently measuring GM-CSF, IFN-g, IL-1b, IL-2, IL-6,
IL-8, IL-10, IL-12p70, and TNF-a by multiplex assay to corre-
late with PCT levels and clinical outcomes. We hypothesize
that PCT will be lower on DO after reduced intensity regimens
given less inflammation and toxicity. More subjects need to be
enrolled to determine whether D0 levels are predictive of toxicity
and whether post-transplant PCT can predict GVHD and/or
infection.315
PHERIPHERAL BLOOD STEM CELL COLLECTION IN AUTOLOGOUS STEM
CELL TRANSPLANTATION, EXPERIENCE IN A SINGLE PEDIATRIC CENTER
IN COLOMBIA
Chaparro, M., Estupi~nan, M. Hospital de la Misericordia, Bogota, DC,
Colombia
Between August 2007 and December 2009 all patients with ma-
lignancies those that were candidates to autologous stem cell
transplantation had been included. All patients were mobilized
by chemotherapy and G-CSF 5 mgr/kg/day, leukapheresis was
performed when the leukocytes were . 1,000/l. All patients had
a long time catheter Hickman-Broviac or high flow hemodyalisis
catheter through a jugular or subclavian vein, inserted by pediatric
surgery team. All procedures were performed by the continuous
flow blood cell separator Amicus- Fenwal by using manufacturer
provided mononuclear cell computer software. The extracorpo-
real volume of the device is 163 ml and the extracorporeal eryth-
rocyte volume is 79 ml during the mononuclear collection phase.
Between all available devices in Colombia Amicus has the lower
extracorporeal volume. Amicus device has been tested in adults
and children. To avoid cardiovascular effects some children with
low hemoglobin level received irradiated packed RBC without
priming the system as described previously in children with
a weigh lower than 15kg.
A total of 16 procedures were performed in 12 patients, 8 females,
and 4 males. Diagnoses were: neuroblastoma n5 8 lymphoma n5 3
(Hodgkin Lymphoma 2, Large B Cell lymphoma 1), Ewing’s Sar-
coma n5 1. Themedian age was 7 years (2- 17 years) and themedian
weigh 23,5 Kg (12- 50 Kg). The median collection time was 281,2
min. (163- 391 min.), the blood volume processed was 8568,6 ml
(range 1349- 5566 ml), blood volume was processed in a median of
2,5 times (range 2,5- 7 times), all procedures were large-volume leu-
kapheresis. Median weight of product was 107 gr. (Range 45- 155
gr.)The median number of PBPC collected was 4,8 mononuclear
cells (MNC)108/kg (range 0,2–21) and 8,41 CD34+ cells106/kg
(range 0.08– 54).
No circulatory side effects were observed during the procedures.
No one patient required sedation and the only symptoms observed
were associated to hypocalcaemia (muscle spasms of hands in tree pa-
tient weighs 14, 15 y 17Kg). In those patients median blood volume
processed was 6,3 times.
